EMA — authorised 7 October 2002
- Application: EMEA/H/C/000442
- Marketing authorisation holder: Novo Nordisk A/S
- Local brand name: Protaphane
- Indication: Treatment of diabetes mellitus.
- Status: approved
🇪🇺 Protaphane in European Union
EMA authorised Protaphane on 7 October 2002
Marketing authorisation
Protaphane in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in European Union
Frequently asked questions
Is Protaphane approved in European Union?
Yes. EMA authorised it on 7 October 2002.
Who is the marketing authorisation holder for Protaphane in European Union?
Novo Nordisk A/S holds the EU marketing authorisation.